Cyclopharm (ASX:CYC) secured a purchase order from the National Institutes of Health and a contract with Texas Health Presbyterian Hospital Dallas, part of Texas Health Resources, according to a Thursday Australian bourse filing.
The company has installed its core radiopharmaceutical product, Technegas, at two sites within the St. Charles Health System, marking its first implementation in the Pacific Northwest, the filing said.
The company's shares jumped almost 4% in recent Thursday trade.